Previous 10 | Next 10 |
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that the Company will p...
2023-05-16 16:56:02 ET Silence Therapeutics press release ( NASDAQ: SLN ): Q1 GAAP EPS of -9.5p. Revenue of £11.37M (+98.8% Y/Y). For further details see: Silence Therapeutics GAAP EPS of -9.5p, revenue of £11.37M
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today reported its financial results fo...
2023-05-08 09:26:30 ET Morgan Stanley has initiated Silence Therapeutics ( NASDAQ: SLN ) with an overweight rating saying that the company's RNAi platform and pipeline, particularly zerlasiran for cardiovascular disease. The firm has a $20 price target (~215% upside based on Fri...
2023-05-04 08:56:54 ET Silence Therapeutics ( NASDAQ: SLN ) announced that AstraZeneca had nominated the first product candidate under its siRNA collaboration and will pay Silence a $10M option fee to advance development on an undisclosed program. Silence and AstraZeneca began...
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that AstraZeneca has no...
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that it has completed e...
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that Company management...
2023-04-14 17:30:31 ET Gainers: Elevation Oncology ( ELEV ) +23% . Kezar Life Sciences ( KZR ) +16% . Vimeo ( VMEO ) +5% . Karyopharm Therapeutics ( KPTI ) +4% . LivaNova ( LIVN ) +3% . Losers: Silence Therapeutics&...
– Study provides therapeutic rationale for SLN124, Silence’s clinical candidate for polycythemia vera and other hematological disorders Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biote...
News, Short Squeeze, Breakout and More Instantly...
Silence Therapeutics Plc Company Name:
SLN Stock Symbol:
NASDAQ Market:
Silence Therapeutics Plc Website:
2024-06-28 10:00:07 ET Keay Nakae from Chardan Capital issued a price target of $55.00 for SLN on 2024-06-28 08:03:00. The adjusted price target was set to $55.00. At the time of the announcement, SLN was trading at $19. The overall price target consensus is at $48.33 wi...
2024-06-28 09:00:06 ET Michael Ulz from Morgan Stanley issued a price target of $49.00 for SLN on 2024-06-28 07:44:00. The adjusted price target was set to $49.00. At the time of the announcement, SLN was trading at $19. The overall price target consensus is at $38.00 wi...
Divesiran eliminated the need for phlebotomy in all well-controlled patients following infrequent dosing and was well tolerated Data support advancing divesiran into Phase 2 Company to host conference call today at 8:30am Eastern Time Silence Therapeutics plc (“Si...